UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

The New England journal of medicine, 2021-03, Vol.384 (12), p.1101-1112

2021

Link zum Volltext

Verfügbarkeit prüfen

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

American journal of clinical dermatology, 2021-09, Vol.22 (5), p.693-707

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial

PloS one, 2016-06, Vol.11 (6), p.e0157045-e0157045

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial

The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2200866-2200866

2023

Link zum Volltext

Verfügbarkeit prüfen

Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life

The Journal of dermatological treatment, 2022-07, Vol.33 (5), p.2605-2613

2022

Link zum Volltext

Verfügbarkeit prüfen

COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study

Immunity & ageing, 2020-08, Vol.17 (1), p.22-22, Article 22

2020

Link zum Volltext

Verfügbarkeit prüfen

Parasitological Clearance Rates and Drug Concentrations of a Fixed Dose Combination of Azithromycin-Chloroquine in Asymptomatic Pregnant Women with Plasmodium Falciparum Parasitemia: An Open-Label, Non-Comparative Study in Sub-Saharan Africa

PloS one, 2016-11, Vol.11 (11), p.e0165692-e0165692

2016

Link zum Volltext

Verfügbarkeit prüfen

Multiple-level stakeholder engagement in malaria clinical trials: addressing the challenges of conducting clinical research in resource-limited settings

Trials, 2018-03, Vol.19 (1), p.190-190, Article 190

2018

Link zum Volltext

Verfügbarkeit prüfen

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE

JAAD international, 2021-09, Vol.4, p.46-48

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-08, Vol.156 (8), p.863

2020

Link zum Volltext

Verfügbarkeit prüfen

Alveolar Proteinosis: The Role of Anti-GM-CSF Antibodies

Archivos de bronconeumología (English ed.), 2018-12, Vol.54 (12), p.601-602

2018

Link zum Volltext

Verfügbarkeit prüfen

Alveolar Proteinosis: The Role of Anti-GM-CSF Antibodies

Archivos de bronconeumología (English ed.), 2018-12, Vol.54 (12), p.601-602

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet (British edition), 2020-07, Vol.396 (10246), p.255-266

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2021-10, Vol.157 (10), p.1165

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

The Lancet (British edition), 2022-07, Vol.400 (10348), p.273-282

2022

Link zum Volltext

Verfügbarkeit prüfen

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Journal of the American Academy of Dermatology, 2022-01, Vol.86 (1), p.104-112

2022

Link zum Volltext

Verfügbarkeit prüfen

426 Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis from the JADE clinical trial program

British journal of dermatology (1951), 2023-06, Vol.188 (Supplement_3)

2023

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479]

Autoimmunity reviews, 2024-02, Vol.23 (2), p.103517, Article 103517

2024

Link zum Volltext

Verfügbarkeit prüfen

Abrocitinib for atopic dermatitis – Authors' reply

The Lancet (British edition), 2021-01, Vol.397 (10270), p.196-196

2021

Link zum Volltext

Verfügbarkeit prüfen

Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study

Journal of allergy and clinical immunology, 2021-02, Vol.147 (2), p.AB156-AB156

2021

Link zum Volltext

Verfügbarkeit prüfen

503 Fetal and neonatal drug exposure following nipocalimab treatment in pregnant women at risk of EOS-HDFN

American journal of obstetrics and gynecology, 2024-01, Vol.230 (1), p.S274-S275

2024

Link zum Volltext

Verfügbarkeit prüfen

232 Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN

American journal of obstetrics and gynecology, 2024-01, Vol.230 (1), p.S138-S138

2024

Link zum Volltext

Verfügbarkeit prüfen

Proteinosis alveolar: rol de los anticuerpos anti-GM-CSF

Archivos de bronconeumología, 2018-12, Vol.54 (12), p.601-602

2018

Link zum Volltext

Verfügbarkeit prüfen

27603 Rapid itch relief with abrocitinib predicts later skin clearance: A post hoc analysis vs dupilumab and placebo in JADE COMPARE

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB155-AB155

2021

Link zum Volltext

Verfügbarkeit prüfen

27582 Abrocitinib improves work productivity through improvement in pruritus and sleep: Results from the JADE MONO-2 study in patients with moderate-to-severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB153-AB153

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 327

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(291)
Mit Volltextzugriff
(307)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial

Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial

Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life

COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study

Parasitological Clearance Rates and Drug Concentrations of a Fixed Dose Combination of Azithromycin-Chloroquine in Asymptomatic Pregnant Women with Plasmodium Falciparum Parasitemia: An Open-Label, Non-Comparative Study in Sub-Saharan Africa

Multiple-level stakeholder engagement in malaria clinical trials: addressing the challenges of conducting clinical research in resource-limited settings

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

Alveolar Proteinosis: The Role of Anti-GM-CSF Antibodies

Alveolar Proteinosis: The Role of Anti-GM-CSF Antibodies

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

426 Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis from the JADE clinical trial program

Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479]

Abrocitinib for atopic dermatitis – Authors' reply

Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study

503 Fetal and neonatal drug exposure following nipocalimab treatment in pregnant women at risk of EOS-HDFN

232 Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN

Proteinosis alveolar: rol de los anticuerpos anti-GM-CSF

27603 Rapid itch relief with abrocitinib predicts later skin clearance: A post hoc analysis vs dupilumab and placebo in JADE COMPARE

27582 Abrocitinib improves work productivity through improvement in pruritus and sleep: Results from the JADE MONO-2 study in patients with moderate-to-severe atopic dermatitis (AD)

Suchergebnisse filtern